On the other hand, treatment with iMGL‐EV downregulated the expression of Map3k14 (mitogen‐activated protein kinase), a pro‐inflammatory gene relevant to AD pathogenesis and the TNF pathway (Rogers et al. 2024; Rudnitskaya et al. 2022). Here, MAP3K14 is linked to Alzheimer disease.